
    
      Primary Objective:

        1. To demonstrate that 68Ga-RM2 and 68Ga-PSMA-11 PET/MRI can detect additional cancers over
           mpMRI.

        2. To demonstrate that 68Ga-RM2 and 68Ga-PSMA-11 PET/MRI can assess changes in response to
           treatment and predict progression free survival (PFS) at 24 months.
    
  